02195nas a2200325   4500000000100000008004100001260001300042653002600055653002400081653003800105653001600143653001100159653002100170653002100191653002500212653002800237653002500265653002100290653000900311100001200320700001700332700001600349700001500365700001500380245013900395300001000534490000700544520130400551022001401855       1989                            d  c1989 Mar10aAntibodies, Bacterial10aAntigens, Bacterial10aEnzyme-Linked Immunosorbent Assay10aGlycolipids10aHumans10aImmunoglobulin G10aImmunoglobulin M10aLeprosy, lepromatous10aMonitoring, Physiologic10aMycobacterium leprae10aRadioimmunoassay10aSkin1 aSinha S1 aMcEntegart A1 aGirdhar B K1 aBhatia A S1 aSengupta U00aAppraisal of two Mycobacterium leprae-specific serological assays for monitoring chemotherapy in lepromatous (LL/BL) leprosy patients.  a24-320 v573 a<p>Two of the Mycobacterium leprae-specific assays--a serum antibody competition (for an epitope on 35-kDa protein) test (SACT) and an enzyme-linked immunosorbent assay (ELISA) for the disaccharide epitope of phenolic glycolipid-I (PGDS)--were comparatively evaluated as tools for monitoring chemotherapy in 125 lepromatous leprosy (LL/BL) patients. An adaptation of the SACT from a radioimmunoassay (RIA) to an ELISA procedure is also described. A moderate but statistically significant correlation was observed between the assays, although SACT appeared to be the more sensitive of the two. Levels of antibodies correlated better with the bacterial index (BI) than with the duration of treatment. However, wide individual variations in antibody levels (for a specific duration of treatment or BI) were seen in treated as well as untreated patients. Anti-PGDS antibody response of the IgG type was poorer than that of the IgM type and, apparently, it did not have a bearing on either treatment duration or the BI. Further studies will be needed to clarify whether the treated patients showing a negative (or low) BI and high antibody levels were harboring hidden foci of active infection, and whether treatment could safely be terminated in patients showing low values for both BI and antibody.</p>  a0148-916X